Controversy is escalating among health professionals following reports that the Centers for Disease Control and Prevention (CDC) intends to finance a discredited vaccine trial exposing newborns in Guinea-Bissau to hepatitis B. This trial poses significant risks, potentially leading to severe liver conditions, including cirrhosis and cancer, as well as premature death.
The trial, which was previously suspended in January due to ethical concerns, has resurfaced in discussions about funding. Reports indicate that CDC officials have instructed the agency’s budget office to allocate $1.6 million for the trial, despite ongoing opposition. This funding would divert resources from other CDC programs aimed at global health security, notably those addressing the current Ebola outbreak in the Democratic Republic of the Congo.
The Department of Health and Human Services, which oversees the CDC, has yet to provide a response regarding these developments. If the trial proceeds, it would be funded by the United States but executed by a research team from Denmark. This team, led by researchers Christine Stabell Benn and Peter Aaby, has faced accusations of misconduct in the past. The CDC awarded them the controversial grant of $1.6 million after they produced research that has often been cited by anti-vaccine advocates, leading to significant skepticism within the scientific community.
In January, amid rising criticism, health officials in Guinea-Bissau announced the suspension of the research, citing the need for thorough ethical and technical assessments of the trial’s structure. Public Health Minister Quinhin Nantote emphasized the lack of adequate coordination, resulting in the decision to halt the study. “Faced with this situation, we decided to suspend it,” he stated.
Editor’s Take
The potential resumption of this trial raises serious ethical questions, reflecting larger tensions between public health objectives and research integrity. If funded, this study could set a precedent for how vulnerable populations are treated in global health research. Stakeholders must consider the implications on trust in healthcare systems, especially in regions facing critical health crises.
Source: arstechnica.com
